

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

5-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11 11-12 13-14  
14-15

exact/norm bonds :

7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15

exact bonds :

5-13 8-13 13-14

normalized bonds :



1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom



chain nodes :

18

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

5-13 14-18

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11 11-12 13-14  
14-15

exact/norm bonds :

7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15 14-18

exact bonds :

5-13 8-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6



isolated ring systems :

containing 1 : 7 :

G1:O,S,N,X,Ak,CN,NO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom  
12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS



ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

5-13

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11  
11-12 13-14 14-15

exact/norm bonds :

7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15

exact bonds :

5-13 8-13 13-14

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

isolated ring systems :

containing 1 : 7 :

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom

10/530,101

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3 JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS 4 AUG 11	STN AnaVist workshops to be held in North America
NEWS 5 AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS 6 AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 OCT 03	MATHDI removed from STN
NEWS 9 OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 10 OCT 06	STN AnaVist workshops to be held in North America
NEWS 11 OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 12 OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 13 OCT 27	Free KWIC format extended in full-text databases
NEWS 14 OCT 27	DIOGENES content streamlined
NEWS 15 OCT 27	EPFULL enhanced with additional content
NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:09:47 ON 29 OCT 2005

=> file reg  
COST IN U.S. DOLLARS

SINCE FILE TOTAL

10/530,101

ENTRY      SESSION  
FULL ESTIMATED COST      0.21      0.21

FILE 'REGISTRY' ENTERED AT 11:09:58 ON 29 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 OCT 2005 HIGHEST RN 866318-76-5  
DICTIONARY FILE UPDATES: 27 OCT 2005 HIGHEST RN 866318-76-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*


Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10530101.str



ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  
chain bonds :

10/530,101

5-13  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11 11-12 13-14  
14-15  
exact/norm bonds :  
7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15  
exact bonds :  
5-13 8-13 13-14  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
isolated ring systems :  
containing 1 : 7 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam

SAMPLE SEARCH INITIATED 11:10:19 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 37 TO ITERATE

100.0% PROCESSED 37 ITERATIONS  
SEARCH TIME: 00.00.01

29 ANSWERS


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 376 TO 1104  
PROJECTED ANSWERS: 257 TO 903

L2 29 SEA SSS SAM L1

10/530,101

=> d scan


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridine-2-methanol, 3-[2-(methylthio)-4-pyrimidinyl]-  
α-phenyl- (9CI)  
MF C19 H16 N4 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):28

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridine-6-carboxylic acid, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)  
MF C28 H29 F N6 O2  
CI COM




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridine-6-carboxamide, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-[2-hydroxy-1-(hydroxymethyl)ethyl]- (9CI)  
MF C31 H36 F N7 O3




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Pyrimidinamine, 5-bromo-4-[5-chloro-2-(4-fluorophenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI)  
MF C22 H18 Br Cl F N5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Pyrimidinamine, 4-[7-chloro-2-(3-methylphenyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI)  
MF C23 H22 Cl N5



10/530,101


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Methanesulfonamide, N-[2-[3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]ethyl]- (9CI)  
MF C26 H31 N7 O3 S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(3-methoxyphenyl)-N,N-dimethyl- (9CI)  
MF C25 H28 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-3-[2-(butylamino)-4-pyrimidinyl]-2-[4-(dimethylamino)phenyl]- (9CI)  
MF C27 H35 N7




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Acetic acid, [4-[7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenoxy]-, ethyl ester (9CI)  
MF C31 H36 N6 O3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(butylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)-N-methyl- (9CI)  
MF C22 H23 F N6



10/530,101


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-methyl-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)  
MF C28 H31 F N6




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[3-(1-piperidinyl)propyl]- (9CI)  
MF C26 H26 F4 N6




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Pyrimidinamine, 4-[2-(3-chlorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[4-(1-pyrrolidinyl)butyl]- (9CI)  
MF C26 H26 Cl F3 N6




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridine, 2-(4-fluorophenyl)-3-[2-(methylthio)-4-pyrimidinyl]-6-(trifluoromethyl)- (9CI)  
MF C19 H12 F4 N4 S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-2-propenyl- (9CI)  
MF C21 H15 F4 N5



10/530,101


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Pyrimidinamine, 4-[2-[2-(cyclopentylamino)-4-pyridinyl]pyrazolo[1,5-a]pyridin-3-yl]-N-(1-methylethyl)- (9CI)  
MF C24 H27 N7




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, 5-chloro-N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)  
MF C27 H28 Cl F N6




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Phenol, 4-[5-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]- (9CI)  
MF C27 H30 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Pyrimidinamine, N-cyclopropyl-4-[2-(4-fluorophenyl)-7-(2,2,2-trifluoroethoxy)pyrazolo[1,5-a]pyridin-3-yl]- (9CI)  
MF C22 H17 F4 N5 O



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, 2-(3-chlorophenyl)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-cyclopropyl- (9CI)  
MF C25 H25 Cl N6



10/530,101


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Phosphoric acid, 4-[(3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-methoxyphenyl)pyrazolo[1,5-a]pyridin-7-yl]amino]butyl bis(phenylmethyl)ester (9CI)  
MF C41 H45 N6 O5 P




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-phenyl- (9CI)  
MF C27 H30 N6




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(4-phenoxyphenyl)- (9CI)  
MF C33 H34 N6 O




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-6-  
[(dimethylamino)methyl]-4-pyrimidinyl]-2-(4-fluorophenyl)- (9CI)  
MF C30 H36 F N7




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, N-butyl-2-(4-fluorophenyl)-3-[2-  
(methylsulfinyl)-4-pyrimidinyl]- (9CI)  
MF C22 H22 F N5 O S




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridin-7-amine, 2-(4-bromophenyl)-N-butyyl-3-[2-(butylamino)-4-pyrimidinyl]- (9CI)  
MF C25 H29 Br N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Pyrimidinamine, 4-[2-(3-chloro-4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-[2-(1-piperidinyl)ethyl]- (9CI)  
MF C25 H23 Cl F4 N6



10/530,101


\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 1,4-Butanediamine, N,N-diethyl-N'-(4-[6-(trifluoromethyl)-2-[4-(trifluoromethyl)phenyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinyl)- (9CI)  
MF C27 H28 F6 N6



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

L2 29 ANSWERS REGISTRY COPYRIGHT 2005 ACS on STN  
IN 2-Pyrimidinamine, 4-[2-(4-fluorophenyl)-6-(trifluoromethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-(2,2,2-trifluoroethyl)- (9CI)  
MF C20 H12 F7 N5



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> log y

COST IN U.S. DOLLARS

FULL ESTIMATED COST



SINCE FILE  
ENTRY

0.43

TOTAL  
SESSION  
0.64

STN INTERNATIONAL LOGOFF AT 11:10:43 ON 29 OCT 2005

10/530,101



chain nodes :  
18  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  
chain bonds :  
5-13 14-18  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11  
11-12 13-14 14-15  
exact/norm bonds :  
7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15 14-18  
exact bonds :  
5-13 8-13 13-14  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
isolated ring systems :  
containing 1 : 7 :

G1:O,S,N,X,Ak,CN,NO2

Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom  
10:Atom 11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS

10/530,101

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611bxv

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1	Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	"Ask CAS" for self-help around the clock
NEWS 3 JUL 20	Powerful new interactive analysis and visualization software, STN AnaVist, now available
NEWS 4 AUG 11	STN AnaVist workshops to be held in North America
NEWS 5 AUG 30	CA/CAplus -Increased access to 19th century research documents
NEWS 6 AUG 30	CASREACT - Enhanced with displayable reaction conditions
NEWS 7 SEP 09	ACD predicted properties enhanced in REGISTRY/ZREGISTRY
NEWS 8 OCT 03	MATHDI removed from STN
NEWS 9 OCT 04	CA/CAplus-Canadian Intellectual Property Office (CIPO) added to core patent offices
NEWS 10 OCT 06	STN AnaVist workshops to be held in North America
NEWS 11 OCT 13	New CAS Information Use Policies Effective October 17, 2005
NEWS 12 OCT 17	STN(R) AnaVist(TM), Version 1.01, allows the export/download of CAplus documents for use in third-party analysis and visualization tools
NEWS 13 OCT 27	Free KWIC format extended in full-text databases
NEWS 14 OCT 27	DIOGENES content streamlined
NEWS 15 OCT 27	EPFULL enhanced with additional content
NEWS EXPRESS	JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* STN Columbus \* \* \* \* \* \* \* \* \* \* \*

FILE 'HOME' ENTERED AT 11:16:49 ON 29 OCT 2005

=> file reg  
COST IN U.S. DOLLARS

SINCE FILE TOTAL

10/530,101

ENTRY SESSION  
FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 11:16:58 ON 29 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 OCT 2005 HIGHEST RN 866318-76-5  
DICTIONARY FILE UPDATES: 27 OCT 2005 HIGHEST RN 866318-76-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*


Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\105301012.str



chain nodes :  
18  
ring nodes :

10/530,101

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  
chain bonds :  
5-13 14-18  
ring bonds :  
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-12 8-9 8-13 9-10 9-15 10-11 11-12 13-14  
14-15  
exact/norm bonds :  
7-8 7-12 8-9 9-10 9-15 10-11 11-12 14-15 14-18  
exact bonds :  
5-13 8-13 13-14  
normalized bonds :  
1-2 1-6 2-3 3-4 4-5 5-6  
isolated ring systems :  
containing 1 : 7 :

G1:O,S,N,X,Ak,CN,NO2

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 18:CLASS

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1 STR



G1 O,S,N,X,Ak,CN,NO2

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam

SAMPLE SEARCH INITIATED 11:17:21 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 36 TO ITERATE

100.0% PROCESSED 36 ITERATIONS  
SEARCH TIME: 00.00.01

1 ANSWERS

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

10/530,101


BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 360 TO 1080  
PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> d scan

L2 1 ANSWERS .REGISTRY COPYRIGHT 2005 ACS on STN  
IN Pyrazolo[1,5-a]pyridine-2-methanol, 3-[2-(methylthio)-4-pyrimidinyl]-  
α-phenyl- (9CI)  
MF C19 H16 N4 O S



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s l1 sss ful  
FULL SEARCH INITIATED 11:17:37 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 637 TO ITERATE

100.0% PROCESSED 637 ITERATIONS 32 ANSWERS  
SEARCH TIME: 00.00.01

L3 32 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
FULL ESTIMATED COST ENTRY SESSION  
161.33 161.54

FILE 'CAPLUS' ENTERED AT 11:17:43 ON 29 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Oct 2005 VOL 143 ISS 19  
 FILE LAST UPDATED: 28 Oct 2005 (20051028/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.  
 They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 13  
 L4 . 3 L3

=> d 15 1-3 bib hitstr  
 L5 NOT FOUND

The L-number entered has not been defined in this session, or it has been deleted. To see the L-numbers currently defined in this session, enter DISPLAY HISTORY at an arrow prompt (>).

=> d 14 1-3 bib hitstr


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
 AN 2004:333716 CAPLUS  
 DN 140:357367  
 TI Preparation of pyrazolopyridines for the prophylaxis or treatment of a herpes viral infection  
 IN Gudmundsson, Kristjan S.; Johns, Brian A.  
 PA Smithkline Beecham Corporation, USA  
 SO PCT Int. Appl., 80 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004033454	A1	20040422	WO 2003-US30334	20030924
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1546148	A1	20050629	EP 2003-759540	20030924
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI	US 2002-415939P	P	20021003		
	WO 2003-US30334	W	20030924		
OS	MARPAT 140:357367				
IT	681261-91-6P, 2-Isobutyl-3-(2-(methylthio)pyrimidin-4-yl)pyrazolo[1,5-a]pyridine 681261-92-7P, 2-Isobutyl-3-(2-(methylsulfinyl)pyrimidin-4-yl)pyrazolo[1,5-a]pyridine 681261-93-8P, N-Cyclopentyl-4-(2-isobutyl)pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine 681261-94-9P, N-Cyclopentyl-4-(2-isobutyl-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine 681261-95-0P, N-Cyclopentyl-4-(2-isobutyl-7-(methylsulfinyl)pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine 681261-97-2P, 2-(Diethoxymethyl)-3-[2-(methylthio)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine 681261-98-3P, 3-[2-				

(Methylthio)pyrimidin-4-yl]pyrazolo[1,5-a]pyridine-2-carboxaldehyde  
**681261-99-4P** **681262-00-0P** **681262-03-3P**,  
 4-(2-Benzylpyrazolo[1,5-a]pyridin-3-yl)-N-cyclopentyl-2-pyrimidinamine  
**681262-04-4P**, 4-(2-Benzyl-7-chloropyrazolo[1,5-a]pyridin-3-yl)-N-  
 cyclopentyl-2-pyrimidinamine  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic  
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP  
 (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrazolopyridines for the prophylaxis or treatment of a  
 herpes viral infection)


RN 681261-91-6 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-(2-methylpropyl)-3-[2-(methylthio)-4-  
 pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681261-92-7 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-(2-methylpropyl)-3-[2-(methylsulfinyl)-4-  
 pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681261-93-8 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-methylpropyl)pyrazolo[1,5-  
 a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 681261-94-9 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-methylpropyl)-7-  
 (methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




10/530, 101


RN 681261-95-0 CAPLUS  
CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(2-methylpropyl)-7-(methylsulfinyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 681261-97-2 CAPLUS  
CN Pyrazolo[1,5-a]pyridine, 2-(diethoxymethyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681261-98-3 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-2-carboxaldehyde, 3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681261-99-4 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-2-methanol, 3-[2-(methylthio)-4-pyrimidinyl]- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)




RN 681262-00-0 CAPLUS  
CN Pyrazolo[1,5-a]pyridine-2-methanol, 3-[2-(cyclopentylamino)-4-pyrimidinyl]- $\alpha$ -phenyl- (9CI) (CA INDEX NAME)



RN 681262-03-3 CAPLUS  
 CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(phenylmethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 681262-04-4 CAPLUS  
 CN 2-Pyrimidinamine, 4-[7-chloro-2-(phenylmethyl)pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




IT 681261-96-1P, N-Cyclopentyl-3-[2-(cyclopentylamino)pyrimidin-4-yl]-2-isobutylpyrazolo[1,5-a]pyridin-7-amine 681262-01-1P  
 681262-02-2P 681262-05-5P 681262-06-6P,  
 N-Cyclopentyl-4-[2-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 681262-07-7P, N-Cyclopentyl-4-[2-(methoxymethyl)-7-(methylsulfanyl)pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine  
 681262-08-8P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(methoxymethyl)pyrazolo[1,5-a]pyridin-7-amine 681262-09-9P  
 681262-10-2P, N-([3-[2-(Methylsulfanyl)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]methyl)-2-propanamine 681262-11-3P,  
 N-Cyclopentyl-4-[2-[(isopropylamino)methyl]pyrazolo[1,5-a]pyridin-3-yl]-2-pyrimidinamine 681262-12-4P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(isopropylamino)methyl]pyrazolo[1,5-a]pyridin-7-amine 681262-13-5P, 4-[7-Chloro-2-[3-(isopropylamino)propyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 681262-14-6P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(isopropylamino)propyl]pyrazolo[1,5-a]pyridin-7-amine 681262-15-7P, 4-[7-Chloro-2-[2-methoxyethoxy)methyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl-2-pyrimidinamine 681262-16-8P, 3-[2-(Cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)methyl]-N-(2-methoxyethyl)pyrazolo[1,5-a]pyridin-7-amine 681262-17-9P, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)methyl]pyrazolo[1,5-a]pyridin-7-amine 681262-18-0P

a]pyridin-7-amine **681262-18-0P**, N-Cyclopentyl-4-(2-isopropylpyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine  
**681262-19-1P**, N-Cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-isopropylpyrazolo[1,5-a]pyridin-7-amine  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of pyrazolopyridines for the prophylaxis or treatment of a herpes viral infection)


RN 681261-96-1 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(2-methylpropyl)- (9CI) (CA INDEX NAME)




RN 681262-01-1 CAPLUS

CN Methanone, [3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl- (9CI) (CA INDEX NAME)



RN 681262-02-2 CAPLUS

CN Methanone, [7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]pyrazolo[1,5-a]pyridin-2-yl]phenyl- (9CI) (CA INDEX NAME)




RN 681262-05-5 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-


10/530,101

pyrimidinyl]-2-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 681262-06-6 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(methoxymethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)




RN 681262-07-7 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(methoxymethyl)-7-(methylthio)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 681262-08-8 CAPLUS



CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(methoxymethyl)- (9CI) (CA INDEX NAME)



10/530,101


RN 681262-09-9 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[3-(1-pyrrolidinyl)propyl]- (9CI) (CA INDEX NAME)




RN 681262-10-2 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-methanamine, N-(1-methylethyl)-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)




RN 681262-11-3 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-methanamine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 681262-12-4 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-methanamine, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 681262-13-5 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-propanamine, 7-chloro-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 681262-14-6 CAPLUS

CN Pyrazolo[1,5-a]pyridine-2-propanamine, 7-(cyclopentylamino)-3-[2-(cyclopentylamino)-4-pyrimidinyl]-N-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 681262-15-7 CAPLUS


CN 2-Pyrimidinamine, 4-[7-chloro-2-[(2-methoxyethoxy)methyl]pyrazolo[1,5-a]pyridin-3-yl]-N-cyclopentyl- (9CI) (CA INDEX NAME)



10/530,101


RN 681262-16-8 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, 3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)methyl]-N-(2-methoxyethyl)- (9CI) (CA INDEX NAME)




RN 681262-17-9 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-[(2-methoxyethoxy)methyl]- (9CI) (CA INDEX NAME)




RN 681262-18-0 CAPLUS

CN 2-Pyrimidinamine, N-cyclopentyl-4-[2-(1-methylethyl)pyrazolo[1,5-a]pyridin-3-yl]- (9CI) (CA INDEX NAME)



RN 681262-19-1 CAPLUS

CN Pyrazolo[1,5-a]pyridin-7-amine, N-cyclopentyl-3-[2-(cyclopentylamino)-4-pyrimidinyl]-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN  
AN 2002:658126 CAPLUS  
DN 137:201324

TI Preparation of 4-(imidazo[1,2-a]pyrid-3-yl/pyrazolo[2,3-a]pyrid-3-yl)-2-arylamino pyrimidines for the treatment of GSK3-related disorders

IN Berg, Stefan; Bhat, Ratan; Hellberg, Sven

PA Astrazeneca AB, Swed.

SO PCT Int. Appl., 71 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
--	------------	------	------	-----------------	------

PI	WO 2002066480	A2	20020829	WO 2002-SE270	20020218
	WO 2002066480	A3	20040401		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2435177	AA	20020829	CA 2002-2435177	20020218
	BR 2002007096	A	20040120	BR 2002-7096	20020218
	EP 1423388	A2	20040602	EP 2002-712572	20020218
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2004522777	T2	20040729	JP 2002-565994	20020218
	ZA 2003006175	A	20041108	ZA 2003-6175	20030808
	NO 2003003677	A	20031002	NO 2003-3677	20030819
	US 2004106574	A1	20040603	US 2003-468605	20030819
PRAI	US 2001-269903P	P	20010220		
	WO 2002-SE270	W	20020218		

OS MARPAT 137:201324


IT 328061-44-5P 328061-67-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-(imidazo[1,2-a]pyrid-3-yl/pyrazolo[2,3-a]pyrid-3-yl)-2-arylamino pyrimidines for the treatment of GSK3-related disorders)

RN 328061-44-5 CAPLUS


CN 2-Propanol, 1-(dimethylamino)-3-[4-[(4-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



10/530,101

RN 328061-67-2 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2-methylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)




IT 328064-22-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of 4-(imidazo[1,2-a]pyrid-3-yl/pyrazolo[2,3-a]pyrid-3-yl)-2-arylamino pyrimidines for the treatment of GSK3-related disorders)

RN 328064-22-8 CAPLUS

CN Pyrazolo[1,5-a]pyridine, 2-methyl-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2005 ACS on STN

AN 2001:152681 CAPLUS

DN 134:193444

TI Preparation of imidazo[1,2-a]pyridinylpyrimidines and pyrazolo[2,3-a]pyridinylpyrimidines as inhibitors of CDK2, CDK4, and CDK6 cell cycle kinases.

IN Thomas, Andrew Peter; Breault, Gloria Anne; Beattie, John Franklin; Jewsbury, Phillip John

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 81 pp.

CODEN: PIXXD2


DT Patent

LA English


FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001014375	A1	20010301	WO 2000-GB3139	20000815
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA	2376293	AA	20010301	CA 2000-2376293	20000815
BR	2000013476	A	20020430	BR 2000-13476	20000815
EP	1214318	A1	20020619	EP 2000-953319	20000815

EP 1214318 B1 20031008  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL  
 JP 2003507478 T2 20030225 JP 2001-518706 20000815  
 AU 757639 B2 20030227 AU 2000-65833 20000815  
 EE 200200080 A 20030616 EE 2002-80 20000815  
 AT 251623 E 20031015 AT 2000-953319 20000815  
 PT 1214318 T 20040227 PT 2000-953319 20000815  
 ES 2208397 T3 20040616 ES 2000-953319 20000815  
 NZ 516740 A 20040924 NZ 2000-516740 20000815  
 RU 2248976 C2 20050327 RU 2002-107128 20000815  
 ZA 2002000028 A 20030402 ZA 2002-28 20020102  
 BG 106383 A 20020930 BG 2002-106383 20020204  
 NO 2002000832 A 20020412 NO 2002-832 20020220  
 US 6855719 B1 20050215 US 2002-69019 20020221  
 HK 1045510 A1 20040319 HK 2002-107002 20020925  
 PRAI GB 1999-19778 A 19990821  
 WO 2000-GB3139 W 20000815  
 OS MARPAT 134:193444  
 IT 328061-44-5P 328061-67-2P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of imidazo[1,2-a]pyridinylpyrimidines and pyrazolo[2,3-a]pyridinylpyrimidines as inhibitors of CDK2, CDK4, and CDK6 cell cycle kinases)  
 RN 328061-44-5 CAPLUS  
 CN 2-Propanol, 1-(dimethylamino)-3-[4-[[4-(2-methylpyrazolo[1,5-a]pyridin-3-yl)-2-pyrimidinyl]amino]phenoxy]- (9CI) (CA INDEX NAME)




RN 328061-67-2 CAPLUS  
 CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-(2-methylpyrazolo[1,5-a]pyridin-3-yl)- (9CI) (CA INDEX NAME)



IT 328064-22-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of imidazo[1,2-a]pyridinylpyrimidines and pyrazolo[2,3-a]pyridinylpyrimidines as inhibitors of CDK2, CDK4, and CDK6 cell cycle kinases)  
 RN 328064-22-8 CAPLUS  
 CN Pyrazolo[1,5-a]pyridine, 2-methyl-3-[2-(methylthio)-4-pyrimidinyl]- (9CI) (CA INDEX NAME)

10/530,101



RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file caold  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 10.62 172.16

FILE 'CAOLD' ENTERED AT 11:18:32 ON 29 OCT 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s 13  
L5 0 L3

=> log y  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.43 172.59

STN INTERNATIONAL LOGOFF AT 11:18:39 ON 29 OCT 2005